…
CardioComm Solutions, Inc. develops advanced software and hardware products, and core laboratory reading services related to electrocardiogram (ECG) and ambulatory arrhythmia monitoring systems for medical and consumer markets worldwide. The company offers consumer health monitoring products, including GEMS mobile ECG, GEMS mobile RPM, HeartCheck CardiBeat " Mobile ECG device, and HeartCheck SMART monitoring. It also provides healthcare professional monitoring products, such as GEMS Sirona, GEMS WIN, and Trident Pro 40L. CardioComm Solutions, Inc. was incorporated in 1989 and is headquartered in Toronto, Canada.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
CardioComm Solutions Inc. is a Canada-listed developer of cardiac monitoring hardware and ECG data management software for clinical and remote diagnostic use. Long-term growth drivers include aging populations and rising adoption of remote cardiac monitoring and digital-health tools, which could support demand for its diagnostic solutions and software services.
Investors may find exposure to cardiac diagnostics and software-service revenue appealing, but public information appears limited and the business faces financing, regulatory/reimbursement and competitive risks.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Income before tax | -0.19M | -0.10M | -0.00M | 0.00M | -0.06M |
| Net income | -0.19M | -0.10M | -0.00M | 0.00M | -0.06M |
| Selling general administrative | 0.64M | 0.81M | 0.62M | 0.81M | 0.77M |
| Gross profit | 0.51M | 0.75M | 0.74M | 0.64M | 0.73M |
| Reconciled depreciation | 0.03M | 0.02M | 0.03M | 0.03M | 0.02M |
| Ebit | - | - | -0.02M | -0.17M | -0.02M |
| Ebitda | - | - | 0.05M | 0.06M | 0.02M |
| Operating income | -0.26M | -0.21M | -0.07M | -0.21M | -0.06M |
| Interest expense | 0.04M | 0.03M | 0.02M | 0.03M | 0.06M |
| Net interest income | -0.04M | -0.03M | -0.02M | -0.03M | -0.06M |
| Total revenue | 0.53M | 0.88M | 1.00M | 0.68M | 0.83M |
| Total operating expenses | 0.79M | 1.08M | 1.07M | 0.89M | 0.90M |
| Cost of revenue | 0.02M | 0.13M | 0.26M | 0.05M | 0.10M |
| Total other income expense net | 0.10M | 0.14M | 0.09M | 0.24M | 0.06M |
| Net income from continuing ops | -0.19M | -0.10M | -0.00M | 0.00M | -0.06M |
| Net income applicable to common shares | - | - | -0.00M | -0.00M | -0.06M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Total assets | 0.22M | 0.34M | 0.28M | 0.49M | 0.36M |
| Other current assets | - | - | - | 0.02M | 0.01M |
| Total liab | 0.50M | 0.85M | 0.69M | 0.91M | 1.03M |
| Total stockholder equity | -0.28M | -0.50M | -0.41M | -0.42M | -0.67M |
| Other current liab | - | - | 0.18M | - | 0.25M |
| Common stock | - | - | 30.22M | - | 29.73M |
| Capital stock | 30.65M | 30.23M | 30.22M | 30.19M | 29.73M |
| Retained earnings | -35.45M | -35.25M | -35.15M | -35.15M | -35.15M |
| Cash | 0.06M | 0.09M | 0.06M | 0.11M | 0.12M |
| Total current liabilities | 0.47M | 0.80M | 0.69M | 0.89M | 1.03M |
| Net debt | 0.17M | 0.33M | 0.27M | 0.29M | 0.17M |
| Short long term debt | 0.23M | 0.42M | 0.32M | 0.40M | - |
| Other stockholder equity | - | - | 4.53M | - | 4.75M |
| Property plant equipment | - | - | 0.03M | 0.05M | 0.03M |
| Total current assets | 0.16M | 0.26M | 0.25M | 0.43M | 0.33M |
| Net tangible assets | - | - | -0.41M | -0.43M | -0.67M |
| Net receivables | 0.03M | 0.10M | 0.14M | 0.26M | 0.11M |
| Long term debt | - | - | - | - | 0.29M |
| Inventory | 0.03M | 0.04M | 0.04M | 0.05M | 0.09M |
| Accounts payable | 0.03M | 0.13M | 0.12M | 0.16M | 0.28M |
| Non current assets total | 0.06M | 0.08M | 0.03M | 0.05M | 0.03M |
| Capital lease obligations | 0.05M | 0.07M | 0.02M | 0.04M | 0.02M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Investments | -0.01M | -0.00M | -0.01M | -0.00M | -0.02M |
| Change to liabilities | - | - | -0.14M | 0.00M | 0.07M |
| Total cashflows from investing activities | - | - | -0.01M | -0.01M | -0.02M |
| Net borrowings | 0.09M | 0.09M | -0.10M | -0.10M | 0.02M |
| Total cash from financing activities | 0.09M | 0.09M | -0.10M | -0.10M | 0.02M |
| Change to operating activities | - | - | 0.00M | 0.00M | -0.00M |
| Net income | -0.19M | -0.10M | -0.00M | 0.00M | -0.06M |
| Change in cash | -0.03M | 0.03M | -0.05M | -0.05M | 0.04M |
| Begin period cash flow | 0.09M | 0.06M | 0.11M | 0.12M | 0.08M |
| End period cash flow | 0.06M | 0.09M | 0.06M | 0.11M | 0.12M |
| Total cash from operating activities | -0.11M | -0.05M | 0.05M | -0.12M | 0.04M |
| Depreciation | 0.03M | 0.02M | 0.02M | 0.03M | 0.02M |
| Change to inventory | 0.01M | -0.00M | 0.01M | 0.01M | -0.02M |
| Change to account receivables | 0.07M | 0.03M | 0.13M | 0.13M | 0.02M |
| Change to netincome | - | - | 0.02M | 0.22M | 0.01M |
| Capital expenditures | 0.01M | 0.00M | 0.00M | 0.00M | 0.01M |
| Change in working capital | 0.02M | 0.02M | 0.01M | -0.37M | 0.07M |
| Stock based compensation | 0.00M | 0.00M | 0.02M | 0.04M | 0.01M |
| Other non cash items | 0.03M | -0.00M | 0.00M | 0.19M | 0.00M |
| Free cash flow | -0.12M | -0.06M | 0.04M | -0.12M | 0.02M |
Sector: Healthcare Industry: Health Information Services
|
Stock Name
|
Change
(CAD) |
Price
(CAD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| EKG CardioComm Solutions Inc. |
- -% |
0.01 | - | - | 5.11 | 64.13 | 6.71 | 8.13 |
| NURS Hydreight Technologies Inc |
-0.14 4.46% |
3.00 | 406.00 | 25.91 | 7.85 | 20.38 | 7.45 | 109.02 |
| ADK Diagnos Inc |
0.01 1.43% |
0.35 | - | 10.00 | 411.24 | 18.74 | 389.06 | -6.16 |
| NXG NexgenRX Inc. |
- -% |
0.66 | 39.00 | 32.68 | 1.55 | 4.64 | 1.39 | 7.84 |
| PTEC Principal Technologies Inc |
0.09 39.13% |
0.32 | - | - | 62.75 | 355.42 | 72.08 | -0.81 |
CardioComm Solutions, Inc. develops advanced software and hardware products, and core laboratory reading services related to electrocardiogram (ECG) and ambulatory arrhythmia monitoring systems for medical and consumer markets worldwide. The company offers consumer health monitoring products, including GEMS mobile ECG, GEMS mobile RPM, HeartCheck CardiBeat " Mobile ECG device, and HeartCheck SMART monitoring. It also provides healthcare professional monitoring products, such as GEMS Sirona, GEMS WIN, and Trident Pro 40L. CardioComm Solutions, Inc. was incorporated in 1989 and is headquartered in Toronto, Canada.
| Name | Title | Year Born |
|---|---|---|
| Mr. Etienne Grima CHE, MSc | CEO, Corp. Sec. & Director | NA |
| Ms. Josee Bertrand CPA | Chief Financial Officer | NA |
| Mr. Simi Grosman MBA | Independent Consultant & Director | NA |
| Mr. Robert E. Caines | Chairman & CFO | NA |
| Mr. Etienne Grima CHE, MSc | CEO, Corporate Secretary & Director | NA |
| Dr. Branislav Vasilijevic Ph.D. | Director of Software Engineering & Director | NA |
| Dr. Branislav Vasilijevic Ph.D. | Director of Software Engineering | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.